Sellas said the treatment was generally well tolerated, with no new safety concerns.
Most treatment-related side effects were mild or moderate, with reactions mainly at the injection site, the company said.
Sellas said the results were statistically significant, with a hazard ratio of 0.59
Sellas Life Sciences (SLS) said on Tuesday that its experimental cancer vaccine, Galinpepimut-S (GPS), significantly improved overall survival in patients with acute myeloid leukemia (AML), with the biotech firm eyeing a potential regulatory filing in the first half of next year.
The company announced that its pivotal Phase 3 Regal trial met its primary goal, with GPS reducing the risk of death by 41% compared with the best available treatment (BAT). The trial also showed a median overall survival (OS) of 24 months, compared with 14.7 months for those receiving BAT.
https://finance.yahoo.com/healthcare/articles/sellas-gps-cuts-death-risk-125915492.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.